| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
167,140,000 |
| Market
Cap: |
270.77(M) |
| Last
Volume: |
2,509,087 |
Avg
Vol: |
1,601,087 |
| 52
Week Range: |
$1.25 - $3.07 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 4.3 |
| Insider 3/6 Months : 4.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The INTERCEPT Blood System, which is based on Co.'s technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Co.'s INTERCEPT Blood System is intented for use with blood components including platelets, plasma and red blood cells. Co. has received U.S. Food and Drug Administration approval for the INTERCEPT Blood System for Cryoprecipitation, which uses Co.'s plasma system to produce INTERCEPT Fibrinogen Complex for the treatment and control of bleeding.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
10,000 |
47,350 |
47,350 |
| Total Buy Value |
$0 |
$16,200 |
$85,505 |
$85,505 |
| Total People Bought |
0 |
1 |
4 |
4 |
| Total Buy Transactions |
0 |
1 |
6 |
6 |
| Total Shares Sold |
370,345 |
370,345 |
370,345 |
632,420 |
| Total Sell Value |
$759,322 |
$759,322 |
$759,322 |
$1,678,628 |
| Total People Sold |
7 |
7 |
7 |
8 |
| Total Sell Transactions |
14 |
14 |
14 |
25 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Green Kevin Dennis |
Chief Financial Officer |
• – – |
2020-08-10 |
4 |
AS |
$6.96 |
$477,678 |
D/D |
(68,585) |
132,396 |
|
6% |
|
| Green Kevin Dennis |
Chief Financial Officer |
• – – |
2020-08-10 |
4 |
OE |
$2.08 |
$166,400 |
D/D |
80,000 |
200,981 |
|
- |
|
| Menard Chrystal |
Chief Legal Officer |
• – – |
2020-08-07 |
4 |
AS |
$7.07 |
$166,930 |
D/D |
(23,621) |
48,585 |
|
-1% |
|
| Anderson Timothy B |
Director |
– • – |
2020-08-07 |
4 |
AS |
$7.10 |
$285,152 |
D/D |
(40,076) |
202,406 |
|
-1% |
|
| Anderson Timothy B |
Director |
– • – |
2020-08-07 |
4 |
OE |
$4.34 |
$190,092 |
D/D |
43,800 |
242,482 |
|
- |
|
| Benjamin Richard J |
Chief Medical Officer |
• – – |
2020-07-07 |
4 |
AS |
$7.20 |
$1,113,044 |
D/D |
(154,583) |
41,763 |
|
-15% |
|
| Benjamin Richard J |
Chief Medical Officer |
• – – |
2020-07-07 |
4 |
OE |
$4.32 |
$708,028 |
D/D |
154,583 |
73,429 |
|
- |
|
| Moore Carol |
SVP Reg. & Quality |
• – – |
2020-06-25 |
4 |
AS |
$7.00 |
$910,000 |
D/D |
(130,000) |
111,751 |
|
-18% |
|
| Moore Carol |
SVP Reg. & Quality |
• – – |
2020-06-25 |
4 |
OE |
$2.08 |
$270,400 |
D/D |
130,000 |
241,751 |
|
- |
|
| Witney Frank |
Director |
– • – |
2020-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,184 |
71,489 |
|
- |
|
| Swisher Daniel N Jr |
Director |
– • – |
2020-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,958 |
59,868 |
|
- |
|
| Anderson Timothy B |
Director |
– • – |
2020-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,184 |
198,682 |
|
- |
|
| Schulze Gail |
Director |
– • – |
2020-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,184 |
47,393 |
|
- |
|
| Moore Carol |
SVP Reg. & Quality |
• – – |
2020-06-01 |
4 |
AS |
$6.50 |
$195,163 |
D/D |
(30,025) |
111,751 |
|
5% |
|
| Moore Carol |
SVP Reg. & Quality |
• – – |
2020-06-01 |
4 |
OE |
$2.28 |
$90,057 |
D/D |
30,025 |
111,776 |
|
- |
|
| Menard Chrystal |
Chief Legal Officer |
• – – |
2020-05-12 |
4 |
S |
$5.67 |
$115,288 |
D/D |
(20,351) |
72,206 |
|
-14% |
|
| Corash Laurence M |
Chief Scientific Officer |
• – – |
2020-04-22 |
4 |
OE |
$3.66 |
$346,968 |
D/D |
94,800 |
1,897,558 |
|
- |
|
| Moore Carol |
SVP Reg. & Quality |
• – – |
2020-03-17 |
4 |
AS |
$3.59 |
$95,921 |
D/D |
(26,684) |
111,751 |
|
81% |
|
| Moore Carol |
SVP Reg. & Quality |
• – – |
2020-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
68,333 |
129,250 |
|
- |
|
| Jayaraman Vivek K |
Chief Commercial Officer |
• – – |
2020-03-17 |
4 |
AS |
$3.59 |
$84,475 |
D/D |
(23,500) |
138,912 |
|
81% |
|
| Jayaraman Vivek K |
Chief Commercial Officer |
• – – |
2020-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
64,583 |
156,371 |
|
- |
|
| Corash Laurence M |
Chief Scientific Officer |
• – – |
2020-03-17 |
4 |
AS |
$3.59 |
$62,907 |
D/D |
(17,500) |
1,802,758 |
|
81% |
|
| Corash Laurence M |
Chief Scientific Officer |
• – – |
2020-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
68,333 |
1,820,258 |
|
- |
|
| Green Kevin Dennis |
Chief Financial Officer |
• – – |
2020-03-17 |
4 |
AS |
$3.59 |
$95,709 |
D/D |
(26,625) |
120,981 |
|
81% |
|
| Green Kevin Dennis |
Chief Financial Officer |
• – – |
2020-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
68,333 |
138,399 |
|
- |
|
536 Records found
|
|
Page 8 of 22 |
|
|
0.14 (7.95%) 
